miRNAs在心肌缺血再灌注损伤细胞凋亡中作用的研究进展

摘要/Abstract

摘要： 心血管疾病（cardiovascular diseases，CVD）是引起人类死亡的首要疾病，缺血性心脏病(ischemic heart disease，IHD)是CVD中引起患者死亡的主要病症之一。目前对于IHD的首要治疗方式为开通血管、恢复血流，而由此出现的心肌缺血-再灌注损伤 (myocardial ischemia-reperfusion injury，MI/RI) 严重困扰着疾病的治疗效果。迄今为止，临床上尚无预防MI/RI的有效策略。细胞凋亡是MI/RI的重要病理生理机制，如能减轻MI/RI后细胞凋亡则可能很大程度上缓解缺血再灌注为患者带来的损伤。MicroRNAs(miRNAs/miRs)是一类短链非编码RNA，通过与mRNA的3′-UTR结合，诱导靶基因沉默，发挥其生物学作用。研究发现miRNAs与包括CVD在内的众多人类疾病相关，也参与调控MI/RI后细胞凋亡，如能进一步明确其调控机制，则可能为MI/RI的预防和治疗带来新的契机。本研究从miRNAs的简介、MI/RI和心肌细胞凋亡以及miRNAs在MI/RI细胞凋亡中的调控作用、miRNAs对MI/RI的潜在治疗等方面进行综述，以期为MI/RI的治疗提供参考借鉴。

关键词: font-size:medium, ">microRNAs；心肌缺血-再灌注损伤；细胞凋亡

Abstract: Cardiovascular diseases (CVD) are the leading cause of death worldwide. Ischemic heart disease (IHD) is one of the main causes of death in CVD patients. Revascularization and blood flow restoration are the primary treatments for IHD， but the subsequent myocardial ischemia-reperfusion injury (MI/RI) substantially hampers the effectiveness of these treatments. There is currently no effective method for preventing MI/RI in clinical practice. After MI/RI， apoptosis is a crucial pathophysiological process. The damage brought on by ischemia/reperfusion may be greatly reduced if apoptosis can be reduced following MI/RI. MicroRNAs (miRNAs/miRs) are a class of short non-coding RNAs that bind to the 3′-UTR of mRNA to induce target gene silencing and play their biological roles. Researches have found that miRNAs are related to many human diseases， including CVD， and also participate in the regulation of cardiomyocyte apoptosis after MI/RI. If the regulatory mechanism can be further clarified， it may bring a new opportunity for the prevention and treatment of MI/RI. This study reviewed from the aspects of the introduction of miRNAs， MI/RI and cardiomyocyte apoptosis， the regulation of miRNAs in MI/RI apoptosis， and the potential treatment of miRNAs for myocardial ischemia-reperfusion injury， in order to provide reference for the treatment of MI/RI.

Key words: font-size:medium, ">microRNAs； Myocardial ischemia-reperfusion injury； Cell apoptosis

中图分类号:

王秀, 杜文涛. miRNAs在心肌缺血再灌注损伤细胞凋亡中作用的研究进展[J]. 中国医药导刊, 2023, 25(5): 471-477.

WANG Xiu, DU Wentao. Research Progress on the Role of miRNAs in Apoptosis of Myocardial Ischemia-Reperfusion Injured Cells[J]. CHINESE JOURNAL OF MEDICINAL GUIDE, 2023, 25(5): 471-477.

参考文献

[1]国家卫生健康委员会.2021中国卫生健康统计年鉴[M]. 北京：中国协和医科大学出版社，2022： 277-307.
     [2]中国心血管健康与疾病报告2020[J]. 心肺血管病杂志，2021，40(9)：885-889.
     [3]Safiri S， Karamzad N， Singh K， et al. Burden of ischemic heart disease and its attributable risk factors in 204 countries and territories，1990-2019[J]. Eur J Prev Cardiol， 2022，29(2)： 420-431.
     [4]Lippi G， Favaloro EJ， Sanchis-Gomar F. Sudden cardiac and noncardiac death in sports：epidemiology， causes， pathogenesis， and prevention[J]. Semin Thromb Hemost， 2018，44(8)： 780-786.
     [5]Thind GS， Agrawal PR， Hirsh B， et al. Mechanisms of myocardial ischemia-reperfusion injury and the cytoprotective role of minocycline： scope and limitations[J]. Future cardiol， 2015，11(1)： 61-76.
     [6]Hausenloy DJ， Yellon DM. Myocardial ischemia-reperfusion injury： a neglected therapeutic target[J]. J Clin Invest， 2013，123(1)： 92-100.
     [7]郑君毅，王霁翔，肖健勇，等. 微小RNA-1在缺氧心肌细胞凋亡中的作用[J]. 天津医药，2014，42(7)：641-644.
     [8]Sheng Z， Lu W， Zuo Z， et al. MicroRNA-7b attenuates ischemia/reperfusion-induced H9C2 cardiomyocyte apoptosis via the hypoxia inducible factor-1/p-p38 pathway[J]. J Cell Biochem， 2019，120(6)： 9947-9955.
     [9]Li K， Zhou P， Li S， et al. MicroRNA-29b reduces myocardial ischemia-reperfusion injury in rats via down-regulating PTEN and activating the Akt/eNOS signaling pathway[J]. J Thromb Thrombolysis， 2022，53(1)： 123-135.
     [10]Hao Y， Yuan H， Yu H. Downregulation of miR-483-5p decreases hypoxia-induced injury in human cardiomyocytes by targeting MAPK3[J]. Cell Mol Biol Lett， 2021，26(1)： 8.
     [11]Lee RC， Feinbaum RL， Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14[J]. Cell， 1993，75(5)： 843-854.
     [12]Griffiths-Jones S， Saini HK， Van Dongen S， et al. miRBase： tools for microRNA genomics[J]. Nucleic Acids Res， 2008，36(Database issue)： D154-D158.
     [13]Tufekci KU， Oner MG， Meuwissen RLJ， et al. The role of microRNAs in human diseases[J]. Methods Mol Biol， 2014，1107： 33-50.
     [14]Ha M， Kim VN. Regulation of microRNA biogenesis[J]. Nat Rev Mol Cell Biol， 2014， 15(8)： 509-524.
     [15]Lewis BP， Burge CB， Bartel DP. Conserved seed pairing， often flanked by adenosines， indicates that thousands of human genes are microRNA targets[J]. Cell， 2005，120(1)： 15-20.
     [16]Juzwik CA， Drake SS， Zhang Y， et al. microRNA dysregulation in neurodegenerative diseases： a systematic review[J]. Progress in Neurobiology， 2019，182： 101664.
     [17]Syeda ZA， Langden SSS， Munkhzul C， et al. Regulatory mechanism of microRNA expression in cancer[J]. Int J Mol Sci， 2020，21(5)：1723.
     [18]Zheng B， Xi Z， Liu R， et al. The function of microRNAs in B-cell development， lymphoma， and their potential in clinical practice[J]. Front Immunol， 2018，9： 936.
     [19]Pauley KM， Cha S， Chan EKL. MicroRNA in autoimmunity and autoimmune diseases[J]. J Autoimmun， 2009，32(3-4)： 189-194.
     [20]Chan EKL， Ceribelli A， Satoh M. MicroRNA-146a in autoimmunity and innate immune responses[J]. Ann Rheum Dis， 2013，72(Suppl 2)： i90-i95.
     [21]Sharma S， Mathew AB， Chugh J. miRNAs： Nanomachines that micromanage the pathophysiology of diabetes mellitus[J]. Advances in Clinical Chemistry， 2017，82： 199-264.
     [22]He X， Kuang G， Wu Y， et al. Emerging roles of exosomal miRNAs in diabetes mellitus[J]. Clin Transl Med， 2021，11(6)： e468.
     [23]Xu J， Chen Z， Wang Y， et al. Several circulating miRNAs related to hyperlipidemia and atherosclerotic cardiovascular diseases[J]. Lipids Health Dis， 2019，18(1)： 104.
     [24]Horita M， Farquharson C， Stephen LA. The role of miR-29 family in disease[J]. J Cell Biochem， 2021，122(7)： 696-715.
     [25]Abkhooie L， Sarabi MM， Kahroba H， et al. Potential roles of MyomiRs in cardiac development and related diseases[J]. Curr Cardiol Rev， 2021，17(4)： e2031253743.
     [26]Li Q， Song X， Zou J， et al. Attenuation of microRNA-1 derepresses the cytoskeleton regulatory protein twinfilin-1 to provoke cardiac hypertrophy[J]. J Cell Sci， 2010，123(Pt 14)： 2444-2452.
     [27]Jayawardena E， Medzikovic L， Ruffenach G， et al. Role of miRNA-1 and miRNA-21 in acute myocardial ischemia-reperfusion injury and their potential as therapeutic strategy[J]. Int J Mol Sci， 2022，23(3)： 1512.
     [28]Liao C， Gui Y， Guo Y， et al. The regulatory function of microRNA-1 in arrhythmias[J]. Mol Biosyst， 2016，12(2)： 328-333.
     [29]Liu Y， Liang Y， Zhang J， et al. MicroRNA-133 mediates cardiac diseases： mechanisms and clinical implications[J]. Exp Cell Res， 2017，354(2)： 65-70.
     [30]Satoh M， Minami Y， Takahashi Y， et al. Expression of microRNA-208 is associated with adverse clinical outcomes in human dilated cardiomyopathy[J]. J Card Fail， 2010，16(5)： 404-410.
     [31]Zhao X， Wang Y， Sun X. The functions of microRNA-208 in the heart[J]. Diabetes Res Clin Pract， 2020，160： 108004.
     [32]Matkovich SJ， Hu Y， Eschenbacher WH， et al. Direct and indirect involvement of microRNA-499 in clinical and experimental cardiomyopathy[J]. Circ Res， 2012，111(5)： 521-531.
     [33]Ling TY， Wang XL， Chai Q， et al. Regulation of the SK3 channel by microRNA-499-potential role in atrial fibrillation[J]. Heart Rhythm， 2013，10(7)： 1001-1009.
     [34]Adachi T， Nakanishi M， Otsuka Y， et al. Plasma microRNA 499 as a biomarker of acute myocardial infarction[J]. Clin Chem， 2010，56(7)： 1183-1185.
     [35]Li C， Wang N， Rao P， et al. Role of the microRNA-29 family in myocardial fibrosis[J]. J Physiol Biochem， 2021，77(3)： 365-376.
     [36]Liu Y， Song J， Lin J， et al. Roles of MicroRNA-122 in cardiovascular fibrosis and related diseases[J]. Cardiovasc Toxicol， 2020，20(5)： 463-473.
     [37]Sewell WH， Koth DR， Huggins E. Ventricular fibrillation in dogs after sudden return of flow to the coronary artery[J]. Surgery， 1955，38(6)： 1050-1053.
     [38]Jennings RB， Sommers HM， Smyth GA， et al. Myocardial necrosis induced by temporary occlusion of a coronary artery in the dog[J]. Arch Pathol， 1960，70： 68-78.
     [39]Braunwald E， Kloner RA. Myocardial reperfusion： a double-edged sword?[J]. J Clin Invest， 1985，76(5)： 1713-1719.
     [40]张雯，宋俊科，杜冠华.缺血再灌注损伤与细胞凋亡信号转导通路[J]. 中国药学杂志，2015，50(7)：565-569.
     [41]Danial NN， Korsmeyer SJ. Cell death： critical control points[J]. Cell， 2004，116(2)： 205-219.
     [42]梁丽梅，黄照河.心肌缺血再灌注损伤发生机制及防治的研究进展[J]. 右江医学，2017，45(3)：365-368.
     [43]周柯，肖骏. MicroRNA-26b-5p表达水平与心肌梗死和细胞凋亡的相关性[J]. 基因组学与应用生物学， 2020，39(10)：4820-4827.
     [44]高英英.微RNA-29b在心肌缺血再灌注损伤中的作用及机制研究[J]. 安徽医药，2019，23(12)：2463-2467.
     [45]Ye Y， Hu Z， Lin Y， et al. Downregulation of microRNA-29 by antisense inhibitors and a PPAR-gamma agonist protects against myocardial ischaemia-reperfusion injury[J]. Cardiovasc Res， 2010，87(3)： 535-544.
     [46]Wang L， Niu X， Hu J， et al. After myocardial ischemia-reperfusion， miR-29a， and Let7 could affect apoptosis through regulating IGF-1[J]. Biomed Res Int， 2015，2015： 245412.
     [47]卢芬，杨晴，邵文君，等. 微小RNA-98-5p靶向Kruppel样转录因子9对大鼠心肌缺血/再灌注损伤的保护作用[J]. 解剖学报， 2022，53(3)：347-353.
     [48]杜虹，张志远，谷小卫，等. 微小RNA-138-5p通过调控Kelch重复蛋白影响缺氧/复氧心肌细胞增殖与凋亡[J]. 安徽医药，2022，26(3)：582-586.
     [49]Cheng J， Wu Q， Lv R， et al. MicroRNA-449a inhibition protects H9C2 cells against hypoxia/reoxygenation-induced injury by targeting the Notch-1 signaling pathway[J]. Cell Physiol Biochem， 2018，46(6)： 2587-2600.
     [50]Nahrendorf M， Swirshi FK， Aikawa E， et al. The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions[J]. J Exp Med， 2007，204(12)： 3037-3047.
     [51]Cao DJ， Schiattarella GG， Villalobos E， et al. Cytosolic DNA sensing promotes macrophage transformation and governs myocardial ischemic injury[J]. Circulation， 2018，137(24)： 2613-2634.
     [52]Fan Q， Tao R， Zhang H， et al. Dectin-1 contributes to myocardial ischemia/reperfusion injury by regulating macrophage polarization and neutrophil infiltration[J]. Circulation， 2019，139(5)： 663-678.
     [53]Tan H， Song Y， Chen J， et al. Platelet-like fusogenic liposome-mediated targeting delivery of mir-21 improves myocardial remodeling by reprogramming macrophages post myocardial ischemia-reperfusion injury[J]. Adv Sci (Weinh)， 2021，8(15)： e2100787.
     [54]Dai Y， Wang S， Chang S， et al. M2 macrophage-derived exosomes carry microRNA-148a to alleviate myocardial ischemia/reperfusion injury via inhibiting TXNIP and the TLR4/NF-κB/NLRP3 inflammasome signaling pathway[J]. J Mol Cell Cardiol， 2020，142： 65-79.
     [55]Zhao J， Li X， Hu J， et al. Mesenchymal stromal cell-derived exosomes attenuate myocardial ischaemia-reperfusion injury through miR-182-regulated macrophage polarization[J]. Cardiovasc Res， 2019，115(7)： 1205-1216.
     [56]Zuo Y， Cheng X， Gu E， et al. Effect of aortic root infusion of sufentanil on ischemia-reperfusion injury in patients undergoing mitral valve replacement[J]. J Cardiothorac Vasc Anesth， 2014，28(6)： 1474-1478.
     [57]Wu Q， Shang Y， Bai Y， et al. Sufentanil preconditioning protects against myocardial ischemia/reperfusion injury via miR-125a/DRAM2 axis[J]. Cell Cycle， 2021，20(4)： 383-391.
     [58]Chang L， Wu Y， Tang J， et al. Remifentanil protects against myocardial ischemia/reperfusion injury via miR-205-mediated regulation of PINK1[J]. J Toxicol Sci， 2021，46(6)： 263-271.
     [59]Yuan M， Meng X， Ma J， et al. Dexmedetomidine protects H9c2 cardiomyocytes against oxygen-glucose deprivation/reoxygenation-induced intracellular calcium overload and apoptosis through regulating FKBP12.6/RyR2 signaling.[J]. Drug Des Devel Ther， 2019，13： 3137-3149.
     [60]Zheng X， Li J， Fan Q， et al. Dexmedetomidine alleviates myocardial ischemia/reperfusion-induced injury and Ca2+ overload via the microRNA-346-3p/CaMKIId axis[J]. Int J Cardiol， 2021，338： 185-195.
     [61]Wang H， Zhu QW， Ye P， et al. Pioglitazone attenuates myocardial ischemia-reperfusion injury via up-regulation of ERK and COX-2[J]. Biosci Trends， 2012，6(6)： 325-332.
     [62]吴若霞，李正阳，任婷，等. 加味丹参饮结合微小核糖核酸21对大鼠心肌细胞的保护机制[J]. 中国临床药理学杂志，2020，36(1)：61-64.
     [63]徐杨，王纬臻，周亚峰.川皮苷调控miR-145-5p/KLF5轴减轻缺氧复氧诱导的大鼠心肌细胞损伤[J]. 中国药师，2021，24(12)：2141-2147.
     [64]王审，许铭明，叶紫恒，等. 涤痰活血舒痹汤上调microRNA-148a表达减轻心肌缺血再灌注损伤的分子机制研究[J]. 浙江中西医结合杂志，2022，32(12)：1084-1089.
     [65]杨龙，刘春明，王正飞，等. 银杏叶提取物对大鼠心肌缺血再灌注损伤的保护作用及机制[J]. 新乡医学院学报，2021，38(11)：1011-1016.
     [66]Shi J， Bei Y， Kong X， et al. miR-17-3p contributes to exercise-induced cardiac growth and protects against myocardial ischemia-reperfusion injury[J]. Theranostics， 2017，7(3)：664-676.
     [67]Hinkel R， Ramanujam D， Kaczmarek V， et al. AntimiR-21 prevents myocardial dysfunction in a pig model of ischemia/reperfusion injury[J]. J Am Coll Cardiol， 2020，75(15)： 1788-1800.
     [68]Sun M， Guo M， Ma G， et al. MicroRNA-30c-5p protects against myocardial ischemia/reperfusion injury via regulation of Bach1/Nrf2[J]. Toxicol Appl Pharmacol， 2021，426： 115637.
     [69]Huang Z， Xu W， Wu J， et al. MicroRNA-374a protects against myocardial ischemia-reperfusion injury in mice by targeting the MAPK6 pathway[J]. Life Sci， 2019，232： 116619.
     [70]石晓欣，邬亦华，昌菁，等. 过表达微RNA-590-3p对大鼠心肌缺血再灌注损伤的保护作用及机制[J]. 新乡医学院学报，2021，38(7)：601-606.

快速检索引用检索图表检索高级检索